The emergence of new diseases, changes in lifestyle, social evolution, the complexity of technological resources as well as many other factors, makes research of new therapeutic solutions an ever pressing necessity.
The BIAL Group invests over 20% of its turnover in R&D. This is our major pledge: we are committed to discovering and developing innovative medicines.
Our R&D centre in Portugal is staffed by international teams of highly qualified people. It comprises chemists, pharmacologists, biochemists, physicians and pharmacists, all of whom are dedicated to finding new drugs, in two major areas of research: neurosciences and cardiology. These teams centralise the initial stages that form the framework of the research process. They collaborate actively in a network of dozens of research units, firms and international institutions.
The R&D department in Porto centralizes all the areas involved in the process of finding new medicinal products: chemical, pharmacological and clinical investigation.
In recognition of BIAL's commitment to research and development, the group is a member of the European Federation of Pharmaceutical Industries and Associations (EFPIA), the respected federation of leading research firms in the European pharmaceutical sector.